Skip to main content

Advertisement

Log in

Management of Recurrence of Symptoms of Gastroesophageal Reflux Disease: Synergistic Effect of Rebamipide with 15 mg Lansoprazole

Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Proton pump inhibitors (PPIs) are effective in healing reflux esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD). Prevention of recurrence of symptoms has become a therapeutic aim in patients with these conditions.

Aims

We investigated the effects of rebamipide, a mucosal protective anti-ulcer agent, on recurrence of reflux symptoms during PPI maintenance therapy.

Methods

Patients with esophagitis of Los Angeles classification A or B were treated with PPIs for 8 weeks. Patients with relief of symptoms were enrolled for further study. Forty-one patients were randomized to maintenance therapy with 15 mg of lansoprazole daily or 15 mg of lansoprazole and 300 mg rebamipide daily, and recurrence of symptoms was monitored over 12 months. In some patients, concentration of rebamipide and interleukin(IL)-8 expression in the esophageal mucosa were estimated.

Results

During the 12-month period, 11/20 patients (52.4%) taking lansoprazole 15 mg daily suffered recurrence of symptoms, compared to 4/20 patients (20%) treated with lansoprazole 15 mg and rebamipide 300 mg daily (P < 0.05). Rebamipide was detected in the esophageal mucosa 90–180 min after oral administration. IL-8 mRNA expression in the esophageal mucosa of patients with rebamipide was significantly decreased compared with that of patients without rebamipide.

Conclusions

Combination therapy with rebamipide and lansoprazole appears to be highly effective in preventing recurrence of symptoms during long-term maintenance treatment for GERD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664.

    Article  CAS  PubMed  Google Scholar 

  2. Tytgat GN. Review article: treatment of mild and severe cases of GERD. Aliment Pharmacol Ther. 2002;16(Suppl 4):73–78.

    Article  PubMed  Google Scholar 

  3. Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61:1801–1833.

    Article  CAS  PubMed  Google Scholar 

  4. Freston JW, Jackson RL, Huang B, Ballard ED II. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs. 2002;62:1173–1184.

    Article  CAS  PubMed  Google Scholar 

  5. Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther. 1997;11:365–372.

    Article  CAS  PubMed  Google Scholar 

  6. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810.

    Article  CAS  PubMed  Google Scholar 

  7. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110.

    Article  CAS  PubMed  Google Scholar 

  8. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3–S11.

    Article  CAS  PubMed  Google Scholar 

  9. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S–13S.

    CAS  PubMed  Google Scholar 

  10. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993;38:1441–1449.

    Article  CAS  PubMed  Google Scholar 

  11. Sun WH, Tsuji S, Tsujii M, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000;295:447–452.

    CAS  PubMed  Google Scholar 

  12. Suetsugu H, Ishihara S, Moriyama N, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136:50–57.

    Article  CAS  PubMed  Google Scholar 

  13. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S–98S.

    Article  CAS  PubMed  Google Scholar 

  14. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202–209.

    Article  CAS  PubMed  Google Scholar 

  15. Udagawa A, Shiota G, Ichiba M, Murawaki Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38:141–146.

    Article  CAS  PubMed  Google Scholar 

  16. Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung. 1992;42:1462–1466.

    CAS  PubMed  Google Scholar 

  17. Naito Y, Yoshikawa T, Tanigawa T. Hydroxyl radicals scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radical Biol Med. 1995;18:117–123.

    Article  CAS  Google Scholar 

  18. Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38:487–494.

    Article  CAS  PubMed  Google Scholar 

  19. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993;43:363–366.

    CAS  PubMed  Google Scholar 

  20. Yoshida N, Yoshikawa T, Iinuma S, et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41:1139–1144.

    Article  CAS  PubMed  Google Scholar 

  21. Murakami K, Okajima K, Harada N, Isobe H, Okabe H. Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci. 1998;43:139S–142S.

    CAS  PubMed  Google Scholar 

  22. Masamune A, Yoshida M, Sakai Y, Shimosegawa T. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther. 2001;298:485–492.

    CAS  PubMed  Google Scholar 

  23. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 1998;43:160S–166S.

    CAS  PubMed  Google Scholar 

  24. Yoshida N, Uchiyama K, Kuroda M, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2004;39:816–822.

    Article  CAS  PubMed  Google Scholar 

  25. Katada K, Yoshida N, Isozaki Y, et al. Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis Sci. 2005;50(Suppl 1):S97–S103.

    Article  CAS  PubMed  Google Scholar 

  26. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.

    Article  CAS  PubMed  Google Scholar 

  27. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998;33:1023–1029.

    Article  CAS  PubMed  Google Scholar 

  28. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75–83.

    Article  CAS  PubMed  Google Scholar 

  29. Naito Y, Yoshikawa T, Iinuma S, et al. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneimittelforschung. 1996;46:698–700.

    CAS  PubMed  Google Scholar 

  30. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989;143:1366–1371.

    CAS  PubMed  Google Scholar 

  31. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124:859–867.

    CAS  PubMed  Google Scholar 

  32. Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S. Italian lansoprazole study group. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol. 2002;97:1357–1364.

    Article  CAS  PubMed  Google Scholar 

  33. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 Suppl):S2–S7.

    Article  PubMed  Google Scholar 

  34. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)—acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.

    Article  CAS  PubMed  Google Scholar 

  35. Yoshida N. Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr. 2007;40:13–23.

    Article  CAS  PubMed  Google Scholar 

  36. Isomoto H, Saenko VA, Kanazawa Y, et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol. 2004;99:589–597.

    Article  CAS  PubMed  Google Scholar 

  37. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol. 1991;104:765–767.

    CAS  PubMed  Google Scholar 

  38. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain. 1995;63:289–302.

    Article  CAS  PubMed  Google Scholar 

  39. Summer GJ, Romero-Sandoval EA, Bogen O, Dina OA, Khasar SG, Levine JD. Proinflammatory cytokines mediating burn-injury pain. Pain. 2008;135:98–107.

    Article  CAS  PubMed  Google Scholar 

  40. Wetscher GJ, Hinder RA, Bagchi D, et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg. 1995;170:552–556.

    Article  CAS  PubMed  Google Scholar 

  41. Olyaee M, Sontag S, Salman W, et al. Mucosal reactive oxygen species production in oesophagitis and Barrett’s oesophagus. Gut. 1995;37:168–173.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Norimasa Yoshida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshida, N., Kamada, K., Tomatsuri, N. et al. Management of Recurrence of Symptoms of Gastroesophageal Reflux Disease: Synergistic Effect of Rebamipide with 15 mg Lansoprazole. Dig Dis Sci 55, 3393–3398 (2010). https://doi.org/10.1007/s10620-010-1166-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1166-9

Keywords

Navigation